The progressive and diffuse nature of neuroblastoma: Treatment with I-131 metaiodobenzylguanidine (I-131 MIBG). S-W
Neuroblastoma is a lethal and not uncommon cancer. In advanced disease, external beam radiation and chemotherapy bring no more than temporary remissions. Most neuroblastomas concentrate I-131 MIBG which then has therapeutic potential for these tumors. The authors treated the neuroblastomas of 7 patients, 20 mos-24 yrs of age, with I-131 MIBG. Factors were examined to explain the results. All but the oldest patient had extensive disease. Scintigraphy portrayed tumor infiltrations of the skeleton not otherwise detectable; in long bones, and, for 2 patients, in hands or feet. Hematopoiesis was precarious from the effects of both tumor and prior chemotherapy. Some tumors produce dopamine, but blockade of receptors was not required prior to I-131 MIBG. I-131 MIBG doses, 60-200 mCi, were scaled for body size. Because of the infiltrative nature of the tumor, rad doses could not be measured. Three had subjective (less pain, more ambulatory) improvement but 1 had enlarging tumors and 1 died; the oldest has not been reevaluated. Four patients died, all of progressive disease. No harmful effects of I-131 MIBG were seen but 1 patient had leukopenia. This paper concludes; I-131 MIBG has the potential to produce benefits in patients with neuroblastoma. But certain factors must be taken into account. Diffuse involvement of marrow will require new approaches to dosimetry, for tumor and for marrow; and the cancer is usually rapidly lethal, and early treatment is necessary.
- Research Organization:
- The Univ. of Michigan Medical Center, Ann Arbor, MI
- OSTI ID:
- 5875037
- Report Number(s):
- CONF-850611-; TRN: 87-039236
- Journal Information:
- J. Nucl. Med.; (United States), Vol. 26:5; Conference: 32. annual meeting of the Society of Nuclear Medicine, Houston, TX, USA, 2 Jun 1985
- Country of Publication:
- United States
- Language:
- English
Similar Records
Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine
Metaiodobenzylguanidine (MIBG) labeled with /sup 123/I//sup 131/I in neuroblastoma diagnosis and follow-up treatment with a review of the diagnostic results of the International Workshop of Pediatric Oncology held in Rome, September 1986
Related Subjects
AUTONOMIC NERVOUS SYSTEM
NEOPLASMS
SCINTISCANNING
METASTASES
DIAGNOSIS
RADIOTHERAPY
MIBG
DIAGNOSTIC USES
THERAPEUTIC USES
DIAGNOSTIC TECHNIQUES
SKELETON
CHEMOTHERAPY
DOSIMETRY
INFANTS
IODINE 131
ORGANIC IODINE COMPOUNDS
PATIENTS
RADIATION DOSES
AGE GROUPS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CHILDREN
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DISEASES
DOSES
DRUGS
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
NERVOUS SYSTEM
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANIC COMPOUNDS
ORGANIC HALOGEN COMPOUNDS
ORGANS
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOLOGY
RADIOPHARMACEUTICALS
THERAPY
USES
550601* - Medicine- Unsealed Radionuclides in Diagnostics
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)
550602 - Medicine- External Radiation in Diagnostics- (1980-)